Shukra Pharmaceuticals Limited

BSE:524632 Stock Report

Market Cap: ₹5.1b

Shukra Pharmaceuticals Past Earnings Performance

Past criteria checks 5/6

Shukra Pharmaceuticals has been growing earnings at an average annual rate of 84.3%, while the Pharmaceuticals industry saw earnings growing at 17% annually. Revenues have been growing at an average rate of 56.1% per year. Shukra Pharmaceuticals's return on equity is 32.2%, and it has net margins of 24%.

Key information

84.3%

Earnings growth rate

59.2%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate56.1%
Return on equity32.2%
Net Margin24.0%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Shukra Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BSE:524632 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 24774185560
31 Dec 231,117185580
30 Sep 2394891560
30 Jun 2374345490
31 Mar 2359544540
31 Dec 2221811590
30 Sep 2224811590
30 Jun 2223910520
31 Mar 222058550
31 Dec 211310540
30 Sep 211441520
30 Jun 211301450
31 Mar 211122450
31 Dec 20110-1430
30 Sep 201211420
30 Jun 201191430
31 Mar 201180490
31 Dec 191048370
30 Sep 19634270
30 Jun 19574220
31 Mar 19575220
31 Dec 1840-5210
30 Sep 18625190
30 Jun 185410150
31 Mar 18535160
31 Dec 176312130
30 Sep 17443130
30 Jun 17527120
31 Mar 17515120
31 Dec 16543110
30 Sep 16451110
30 Jun 16502110
31 Mar 16481120
31 Dec 15193160
30 Sep 15196160
30 Jun 15222110
31 Mar 15261120
31 Dec 14407110
30 Sep 14482100
30 Jun 1446-290
31 Mar 1444-8120
31 Dec 1345-39110
30 Sep 1344-35110
30 Jun 1356-29110

Quality Earnings: 524632 has a high level of non-cash earnings.

Growing Profit Margin: 524632's current net profit margins (24%) are higher than last year (7.4%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 524632's earnings have grown significantly by 84.3% per year over the past 5 years.

Accelerating Growth: 524632's earnings growth over the past year (320.7%) exceeds its 5-year average (84.3% per year).

Earnings vs Industry: 524632 earnings growth over the past year (320.7%) exceeded the Pharmaceuticals industry 18.4%.


Return on Equity

High ROE: 524632's Return on Equity (32.2%) is considered high.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.